Biotech Startups

GoodGut develops intellectual property based on the study of individuals' gut microbiota, which plays a role in intestinal immunity and the development of digestive diseases. The company aims to provide diagnostic solutions for digestive conditions to the healthcare system.

1 investor

Gordion uses AI-driven analysis of patient-derived data to validate oncology drug targets before clinical development. The company serves pharmaceutical and biotech organizations developing cancer treatments.

1 investor

GRA Nutra develops fermentation-based and algae-derived formulated ingredients, supplying natural colors, carotenoids, vitamins, and specialty ingredients to the food & beverage, supplement, and pet food industries. Founded in 2021, the company combines fermentation and algae production technologies with formulation and commercial expertise.

1 investor

Gradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.

1 investor

GRAIL develops a blood-based multi-cancer early detection test called Galleri that uses next-generation sequencing and machine learning to screen for multiple cancer types before symptoms appear. The company serves healthcare providers, insurers, and patients seeking early cancer detection.

1 investor

Grandomics develops third-generation sequencing services and precision genomic medicine solutions for medical diagnostics, plant and animal breeding, and species conservation. The company applies long-read sequencing technology and computational methods to assemble complete genomes and address applications in medicine, crop improvement, and biodiversity protection.

1 investor

Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases. The company targets multiple molecular pathways to reduce disease burden and restore biological balance.

1 investor

GRAVL provides digital infrastructure software for research facilities and core labs, enabling scientists to access scientific tools and services. The platform streamlines operations and management for academic and research institutions.

1 investor

Green Elephant Biotech manufactures 96-well microplates and related lab consumables for life science research. The company sells through authorized distributors across Europe and the United States, as well as directly to labs.

1 investor

GreenGrahi uses Black Soldier Fly biotechnology to convert organic waste into ingredients for animal feed, pet food, and agriculture. The company develops insect-based products and processes aimed at creating a sustainable alternative to conventional organic waste management.

1 investor

Green Spot develops fermentation-based ingredients for industrial use by translating natural biological processes into scalable production systems. The company serves ingredient and formulation companies seeking sustainable alternatives to extractive or scarce resources.

1 investor

Greenfluidics designs living façades—integrated biological systems for building exteriors—that bring nature into urban environments. The company serves architects, developers, institutions, and global brands seeking to reconnect cities with natural spaces.

1 investor

GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.

1 investor

Green Sage Prebiotics develops natural prebiotic solutions to reduce infections and improve health in aquaculture (shrimp and salmon), pets, and humans. The company addresses antibiotic-resistant diseases and premature mortality in farmed seafood, as well as recurring infections in human and animal populations.

1 investor

GreenVenus develops improved crop varieties including leafy greens, grapes, berries, avocados, beans, and lentils using breeding technologies focused on traits such as longer shelf-life, improved flavor, and higher yields.

1 investor

Grenova develops laboratory technology for washing and reusing pipette tips and microwell plates, aimed at labs seeking to reduce consumable waste and costs. The company operates in the life sciences lab equipment and sustainability space.

1 investor

Grey Matter Neurosciences develops transcranial focused ultrasound systems combined with drug therapies to treat mood and cognitive disorders in older adults, with an initial focus on non-invasive neuromodulation outside hospital settings.

1 investor

Grown Alchemist develops high-performance skincare products that combine botanically-sourced ingredients with biotechnology, designed for consumers focused on skin health and wellness. The company operates flagship stores in Melbourne, London, and Hong Kong, and distributes through premium retailers globally.

1 investor

2NA FISH develops a spatial RNA detection platform using nanostructure-enhanced probes for oncology research and pathology workflows. The platform combines brightfield RNA biomarker analysis on standard fluorescence microscopes with AI-powered software for quantification and cell-level readouts.

1 investor

GT Bio develops an in vivo drug delivery atlas that combines drug delivery, targeted conjugates, spatial biology, and machine learning to enable cell type-specific delivery for precision medicine. The company generates in vivo delivery data intended to support the development of next-generation drug delivery systems for patients.

1 investor

Disruptive Pharma AB (formerly Guard Therapeutics International AB) is a pharmaceutical company listed on Nasdaq First North Growth Market under the ticker DPHA. The page contains shareholder and stock information but does not describe the company's products, therapeutic focus, or target markets.

1 investor

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

1 investor

1 investor

Gutcrine is a Danish biotech developing pharmabiotics derived from gut microbiome hormone synthesis, aimed at the prevention and treatment of cardio-metabolic disorders.

1 investor